Ruxolitinib (Jakafi)

Indications

Myelofibrosis (see Primary Myelofibrosis, Primary Myelofibrosis)

  • xxxx

Polycythemia Vera (see Polycythemia Vera, Polycythemia Vera)

  • xxx

Psoriasis (see Psoriasis, Psoriasis)

  • xxxx

Rheumatoid Arthritis (RA) (see Rheumatoid Arthritis, Rheumatoid Arthritis)

  • xxxx

Pharmacology

  • Janus Kinase (JAK) Inhibitor
    • Preferentially Active Against JAK-1 and JAK-2

Metabolism

  • xxxx

Administration

  • xxxx

Dose Adjustment

  • Hepatic:
  • Renal:

Adverse Effects

Hematologic Adverse Effects

Pulmonary Adverse Effects

Other Adverse Effects


References

  • Serious adverse events during ruxolitinib treatment discontinuation in patients with myelofibrosis. Mayo Clin Proc 2011;86:1188–1191.
  • JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med 2012;366:787–798
  • A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 2012;366:799–807
  • Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I. Haematologica 2013;98: 1865–1871
  • Ruxolitinib withdrawal syndrome leading to tumor lysis. J Clin Oncol 2013;31:e430–e432.
  • Recurrent hypoxemic respiratory failure. Beyond the usual suspects. Ann Am Thorac Soc. 2014 Sep;11(7):1145-8. doi: 10.1513/AnnalsATS.201403-127CC [MEDLINE]
  • Acute respiratory distress syndrome in a patient with primary myelofibrosis after ruxolitinib treatment discontinuation. Int J Hematol. 2014 Nov;100(5):498-501. doi: 10.1007/s12185-014-1628-5. Epub 2014 Jul 18 [MEDLINE]